Mr. Stefano Picone reports

CONAVI MEDICAL CORP. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

Conavi Medical Corp. has provided the pricing and terms of its previously announced public offering. The offering is of common shares of the company or prefinanced common share purchase warrants of the company in lieu of common shares.

The offering is being conducted on a commercially reasonable efforts agency basis for the issuance of a minimum of 37.5 million securities and a maximum of 50 million securities at a price of 40 cents per common share or 39.999 cents per prefinanced warrant for gross proceeds of between $15-million and $20-million. Each prefinanced warrant issued in lieu of a common share at the election of any purchaser entitles the holder thereof to acquire one common share at an exercise price of 0.001 cent per common share. The prefinanced warrants will not expire.

The company intends to use the net proceeds from the offering to advance and complete the development and preclinical testing of its Novasight 3.0 technology, with the goal of submitting a 510(k) clearance application to the U.S. Food and Drug Administration in Q3 2025. The company also intends to use the net proceeds for working capital and other general corporate purposes.

The offering is expected to be completed pursuant to the terms and conditions of an agency agreement entered into between the company and Bloom Burton Securities Inc.

The company will file today a final short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario. There will not be any sale of securities until a receipt for the final prospectus has been issued.

The offering is expected to close on or about April 22, 2025, or such other date as may be mutually agreed to by the company and the agent. The offering is subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the TSX Venture Exchange.

The company will pay to the agent a cash fee equal to 7.0 per cent of the gross proceeds raised under the offering and grant the agent compensation options equal to 7.0 per cent of the aggregate number of securities issued under the offering, provided, however, the agent will receive a reduced cash commission of 3.5 per cent and no compensation options in respect of securities sold to certain purchasers on a president list to be agreed to between the company and the agent. Each compensation option shall entitle the agent to buy one common share at the same price per common share as under the offering. The compensation options shall be exercisable until that date that is 24 months following the closing date.

In addition, the securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws.

Access to the amended and restated preliminary prospectus dated March 20, 2025, the final prospectus and any amendments to such documents will be provided in accordance with securities legislation relating to procedures for providing access to a short form prospectus and any amendment thereto. The amended and restated prospectus is and the final prospectus will be accessible on SEDAR+. Alternatively, an electronic or paper copy of the amended and restated prospectus and the final prospectus (when filed) and any amendment to such documents may be obtained without charge, from the agent by e-mail at ECM@bloomburton.com, by telephone at 416-640-7585, or by providing the contact with an e-mail address or address, as applicable. The amended and restated prospectus and the final prospectus (when filed) contain important, detailed information about the company and the offering. Prospective investors should read the amended and restated prospectus and the final prospectus (when filed) before making an investment decision.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight hybrid system is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight hybrid system has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.